NCT01822041View on ClinicalTrials.gov

14C-ARN-509 Microtracer Label AME and Absolute BA Study

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Healthy
Interventions
DRUG

ARN-509

Single oral dose of 240 mg ARN-509

Trial Locations (1)

Unknown

PRA - Clinical Research Unit, University Medical Centre Groningen, Groningen

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY